<div>
  <ul>
    <li>
      <p>
        Drug development company BioAge Labs has secured USD 170 million in an oversubscribed Series D funding round led by Sofinnova Investments, with the participation of new investors like Longitude Capital, RA Capital, Cormorant Asset Management, and existing investor Andreessen Horowitz.
      </p>
    </li>
    <li>
      <p>
        The funds will be used to advance Phase II clinical development of the company's flagship compound, azelaprag, a drug to treat obesity. Clinical investigations for the drug are expected to start in mid-2024 in association with Eli Lilly's Chorus organization.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.businesswire.com/news/home/20240213546755/en/">
      Press release
    </a>
  </p>
  <p>
    <a href="https://www.marketwatch.com/press-release/bioage-announces-170-million-oversubscribed-series-d-financing-to-accelerate-development-of-obesity-and-metabolic-disease-therapeutics-f858af41">
      Market Watch
    </a>
  </p>
</div>


Longevity Tech

<div>
 <p>Pharmaceutical company BioAge Labs has collected a funding of USD 170 million in a series D round that was oversubscribed. The funding round was led by Sofinnova Investments, and was participated in by both new investors such as Longitude Capital, RA Capital and Cormorant Asset Management, and existing investor Andreessen Horowitz.</p>
 <p>The company aims to utilize this funding for progressing towards the Phase II clinical development of its primary compound, azelaprag. This drug is being developed for obesity treatment. The clinical trials for the same are scheduled to commence in mid-2024, and will be done in collaboration with Eli Lilly's Chorus organization.</p>
 
</div>

BioAge Labs raises USD 170 million in oversubscribed Series D funding for clinical development

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

<div>
 <p>BioAge Labs, a drug development company, has recently raised USD 170 million in a Series D funding round that was oversubscribed. The round was led by Sofinnova Investments and saw participation from new investors including Longitude Capital, RA Capital, Cormorant Asset Management, and an existing investor, Andreessen Horowitz.</p>
 <p>The funding will be utilized to propel the Phase II clinical development of azelaprag, the company's main drug which is aimed at treating obesity. The clinical studies for this drug are planned to commence in mid-2024 with the assistance of Eli Lilly's Chorus organization.</p>

</div>

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 <p>BioAge Labs, a drug development company, has successfully raised USD 170 million in a Series D funding round that was oversubscribed. The funding round was led by Sofinnova Investments and also saw participation from new investors such as Longitude Capital, RA Capital, and Cormorant Asset Management, in addition to existing investor Andreessen Horowitz.</p>
 <p>The raised capital will be utilized to further the Phase II clinical development of BioAge Labs' lead compound, azelaprag, a prospective drug for obesity treatment. The commencement of clinical investigations for this drug is planned for mid-2024, in partnership with Eli Lilly's Chorus organization.</p> 
</div>

All Updates

BioAge Labs raises USD 170 million in oversubscribed Series D funding for clinical development

BioAge Labs raises USD 170 million in oversubscribed Series D funding for clinical development

BioAge Labs raises USD 170 million in oversubscribed Series D funding for clinical development